Background: The CD30-positive lymphoproliferative disorders lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (C-ALCL), and systemic anaplastic large cell lymphoma (S-ALCL) are lesions that overlap clinically, histopathologically, and immunophenotypically. Their biologic behaviors, however, vary considerably. In particular, lesions of LyP regress spontaneously while those of S-ALCL persist and often progress. Apoptosis has been suggested as the mechanism by which the lesions of LyP regress, but the underlying signaling pathways remain unclear. In this study, we used newly developed activation state-specific antibodies to demonstrate apoptosis signaling through the death receptor-mediated pathway regulated by FADD and caspase 3.

Methods: Dual immunohistochemistry for CD30 and activated forms of FADD and caspase 3 was performed on cutaneous biopsy specimens from 27 patients with CD30-positive lymphoproliferative disorders involving the skin. The patients included 18 with primary cutaneous CD30-positive LPDs (15 with LyP and 3 with C-ALCL) and 9 with S-ALCL.

Results: The proportion of CD30-positive cells expressing activated FADD was significantly different between primary cutaneous CD30-positive lymphoproliferative disorders and S-ALCL (36.4% vs. 14.5%, P = 0.0083). Expression of cleaved caspase 3 was also significantly different between primary cutaneous lesions and S-ALCL (9.2% vs. 1.9%, P = 0.048).

Conclusions: Although a larger number of cases should be studied to validate these results, these data provide evidence that differences in signaling through the death-receptor apoptosis pathway mediated by FADD may be responsible for the varying biologic behaviors of CD30-positive lymphoproliferative disorders involving the skin.

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.pas.0000155154.46434.93DOI Listing

Publication Analysis

Top Keywords

cd30-positive lymphoproliferative
20
lymphoproliferative disorders
20
primary cutaneous
16
disorders involving
12
involving skin
12
apoptosis signaling
8
mediated fadd
8
anaplastic large
8
large cell
8
cell lymphoma
8

Similar Publications

DUSP22-rearranged primary cutaneous CD30-positive T-cell lymphoproliferative disorders and adult T-cell leukemia/lymphoma frequently share the LEF1+/TIA1- immunophenotype.

Hum Pathol

August 2024

Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan; Department of Pathology, Taipei Medical University Hospital, Taipei, 110, Taiwan; Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 704, Taiwan. Electronic address:

Article Synopsis
  • DUSP22 rearrangements are genetic changes found in certain types of lymphomas, particularly in systemic and primary cutaneous anaplastic large cell lymphoma, as well as lymphomatoid papulosis, with previous studies mainly highlighting S-ALCL.
  • This study examined LEF1/TIA1 expression and MSC mutations in 23 cases of C-ALCL and LyP, finding DUSP22 rearrangements in eight cases and LEF1 expression present in 63% of those cases, while TIA1 was negative across the board.
  • The research indicated that the rate of LEF1 expression in DUSP22-rearranged C-ALCL/LyP is lower than that in S-ALCL
View Article and Find Full Text PDF
Article Synopsis
  • The study focused on the clinicopathological features and differential diagnosis of primary mucosal CD30-positive T-cell lymphoproliferative disorders (pmCD30TLPD) by reviewing cases diagnosed between 2013 and 2023.
  • Eight cases were analyzed, revealing that most patients were middle-aged, with lesions primarily in the oral and anal mucosa, showing various morphological characteristics and immunophenotypes.
  • Despite the potential for misdiagnosis with other lymphoproliferative disorders, most patients had favorable outcomes, with only one succumbing to complications, emphasizing the importance of careful diagnosis and monitoring.
View Article and Find Full Text PDF
Article Synopsis
  • - Brentuximab vedotin (BV) is an effective treatment for refractory CD30+ mycosis fungoides and primary cutaneous anaplastic large-cell lymphoma, showing promising results in a study with Japanese patients.
  • - The study involved two groups: one with CD30+ mycosis fungoides and pcALCL, and another with different CD30+ lymphoproliferative disorders, with treatment cycles continuing based on patient response.
  • - The primary endpoint demonstrated a high objective response rate (69.2% for cohort 1 and 62.5% for cohort 2), with manageable side effects such as peripheral neuropathy and fever in some patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!